AITG Air Transport Group Holdings

Pharmagreen Biotech Inc. (f/k/a Air Transport Group Holdings, Inc.) Update

Pharmagreen Biotech Inc. (f/k/a Air Transport Group Holdings, Inc.) Update

Carson City, Nevada, July 03, 2018 (GLOBE NEWSWIRE) -- Pharmagreen Biotech Inc. (“Pharmagreen Biotech”) (“the Company”) (OTC PINK: AITGD), incorporated under the laws of Nevada, announces that during May 2018, it completed the share exchange agreement entered into on April 12, 2018 with WFS Pharmagreen Inc., a private company incorporated under the Corporations Act of British Columbia, Canada.  With the completion of this transaction the stakeholders of WFS Pharmagreen Inc. held approximately 95.5% of voting control of the Company.  This transaction is treated as a reverse merger with WFS Pharmagreen Inc., being the acquirer and the Company being the acquiree.  In connection with this transaction, the Company intends to change its year end from April 30th to September 30th.  The shares issued are subject to restrictions under applicable securities law.

Furthermore, the name of the Company was changed from Air Transport Group Holdings, Inc. to Pharmagreen Biotech Inc. to reflect the new direction and business of the Company.  With this change, there was a reverse split of 1:200 of the issued and outstanding shares of the Company effective July 2, 2018.  A new symbol “AITGD” replaces the current symbol “AITG” for a period of 20 business days and thereafter will be replaced by the symbol “PHBI”.

About Pharmagreen Biotech, Inc. and WFS Pharmagreen Inc.

WFS Pharmagreen Inc. is a wholly owned Canadian based subsidiary of Pharmagreen Biotech, Inc., a publicly traded (OTC PINKS: AITGD) company.  WFS Pharmagreen Inc. is a cannabis company that is becoming the largest producer of cannabis plantlets through a proprietary tissue culture process with opportunity to become one of the largest players globally.  Pharmagreen’s mission is to advance the technology of tissue culture science and to provide the highest quality 100% germ free, disease free and all genetically the same plantlets of cannabis and other flora while offering full spectrum DNA testing for plant identification, live genetics preservation using  low temperature storage for various cannabis and horticulture plants; extraction of botanical oils mainly CBD oil, and to deliver laboratory based services to the North American Cannabis and agriculture sectors.  For further information on the company progress on the construction of a 60,000 square foot “Cannabis Biotech Complex” please visit

Safe Harbor Statement

This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. In particular, factors that could cause actual results to differ materially from those in forward looking statements include: our inability to obtain additional financing on acceptable terms; risk that our products and services will not gain widespread market acceptance; inability to compete with others who provide comparable products; the failure of our technology; the infringement of our technology with proprietary rights of third parties; inability to respond to consumer demands; inability to replace significant customers; seasonal nature of our business. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements. When used in this document, the words "believe," "expect," "anticipate," "estimate," "project," "plan," "should," "intend," "may," "will," "would," "potential," and similar expressions may be used to identify forward-looking statements.

The OTC Markets or any other securities regulatory authority has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release that has been prepared by management.

Contact Information:

Tel: (702) 803 9404 
Email:  
EN
03/07/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Air Transport Group Holdings

 PRESS RELEASE

PHBI – Pharmagreen Starts Sales of MaxGenomicTM Supplement on Amazon.c...

PHBI – Pharmagreen Starts Sales of MaxGenomicTM Supplement on Amazon.com and Develops Its Next Pre-Workout Formulation CARSON CITY, NV, Sept. 05, 2023 (GLOBE NEWSWIRE) -- via – Pharmagreen Biotech, Inc., (OTC PINKS: PHBI), “Pharmagreen” or the “Company” is pleased to announce that it has been approved by Amazon Seller Central for online sales via Amazon’s e-commerce platform for its MaxGenomicTM Supplement. The company is also developing additional sales channels, both online and brick-and-mortar, for the MaxGenomicTM supplements. Pharmagreen’s long term focus is to develop organic form...

 PRESS RELEASE

PHBI Pharmgreen Launches Online Sales for Its MaxGenomic™ Supplement P...

PHBI Pharmgreen Launches Online Sales for Its MaxGenomic™ Supplement Product CARSON CITY, NV, Feb. 08, 2023 (GLOBE NEWSWIRE) -- via – Pharmagreen Biotech, Inc., (OTC PINKS: PHBI), “Pharmagreen” or the “Company” is pleased to announce that it has completed development of its first formulated nutraceutical product and has commenced online sales via the Shopify ecommerce platform of its MaxGenomic™ Supplement.  The company is also pleased to have entered the nutraceutical industry with this product development and be part of this multi-hundred-billion-dollar industry that is growing at a rec...

 PRESS RELEASE

Pharmagreen Appoints Tyrell Crosby, a Professional Athlete, as Its Hon...

Pharmagreen Appoints Tyrell Crosby, a Professional Athlete, as Its Honorary Sports Ambassador CARSON CITY, NV, Nov. 29, 2022 (GLOBE NEWSWIRE) -- via – Pharmagreen Biotech, Inc., (OTC PINKS: PHBI), (“Pharmagreen” or the “Company”) is pleased to announce that Mr. Tyrell Crosby, a professional NFL player, has joined the Pharmagreen team to be an Honorary Sports Ambassador for Pharmagreen’s NutraMax Genomic Supplement product line. Tyrell will attend gatherings, trade shows, and other scheduled events selected by Pharmagreen, and will provide his endorsement of NutraMax products on various on...

 PRESS RELEASE

PHBI Pharmagreen Biotech Appoints Ethan Styles as Vice President of Pr...

PHBI Pharmagreen Biotech Appoints Ethan Styles as Vice President of Product Research and Development CARSON CITY, NV, Sept. 22, 2022 (GLOBE NEWSWIRE) -- via Pharmagreen Biotech, Inc., (OTCQB: PHBI), (“Pharmagreen” or the “Company) is pleased to announce that Ethan Styles has joined the Pharmagreen team in the role of Vice President of Product Research and Development. Mr. Styles’ lifelong work with therapeutic plants, cannabis, medicinal plants and fungi, combined with years of personal studies in molecular biology, has provided Ethan with keen insight into the human health benefits prov...

 PRESS RELEASE

PHBI Pharmagreen Develops a Proprietary Nutraceutical Formulation and ...

PHBI Pharmagreen Develops a Proprietary Nutraceutical Formulation and Prepares for Product Launch CARSON CITY, Sept. 08, 2022 (GLOBE NEWSWIRE) -- via – Pharmagreen Biotech, Inc., (OTCQB: PHBI), (“Pharmagreen” or the “Company” is pleased to announce that it has developed its first formulated nutraceutical product and is in the process of organizing the retail sales distribution channels for its new product. The Pharmagreen team is very excited to be launching this nutraceutical product utilizing a combination of fifteen ingredients from medicinal plants and mushrooms. Pharmagreen’s propri...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch